Michael A. Metzger - Jul 6, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Jul 6, 2022
Transactions value $
-$222,012
Form type
4
Date filed
7/8/2022, 05:51 PM
Previous filing
Jul 7, 2022
Next filing
Jul 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $95.8K +15K +84.99% $6.38 32.7K Jul 6, 2022 Direct
transaction SNDX Common Stock Sale -$316K -15K -45.94% $21.07 17.7K Jul 6, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $638 +100 +0.57% $6.38 17.8K Jul 7, 2022 Direct
transaction SNDX Common Stock Sale -$2.1K -100 -0.56% $21.00 17.7K Jul 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -15K -100% $0.00* 0 Jul 6, 2022 Common Stock 15K $6.38 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -100 -100% $0.00* 0 Jul 7, 2022 Common Stock 100 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $21.00 to $21.25.
F3 This option vests periodically upon the Issuer achieving certain milestones.